Skip to main content

Day: June 27, 2024

Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global

Kane Also Signs Long-Term Manufacturing Agreement With Halo Pharma WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product (“revyve™”) to ProgenaCare Global LLC (“ProgenaCare”). Kane has now completely fulfilled its obligation related to the USD$500,000 initial manufacturing scale up fee received upon signing an exclusive distribution agreement for the US wound care market in May 2023, after receiving U.S. Food and Drug Administration 510(k) clearance for revyve™ Antimicrobial Wound Gel. Kane has subsequently been working with Halo Pharma on the technology transfer and manufacturing scale-up phases of product commercialization. “This is another...

Continue reading

Calendar Retailer Chooses Bridgeline’s AI-Powered HawkSearch

WOBURN, Mass., June 27, 2024 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a global leader in AI-powered marketing technology, today announced a large calendar retailer has chosen Bridgeline’s HawkSearch to power product discovery for its eCommerce website. HawkSearch will enhance the retailers’ revenue through its AI-powered search bar that offers a more personalized user experience. The calendar retailer will use HawkSearch to increase sales using features such as Smart Search and Recommendations. For instance, if a customer searches for a “day planner with motivational quotes and cute dogs,” Smart Search will display results such as “Dogma, A Dog’s Guide to Life” featuring inspiring quotes paired with photos of dogs. The improved website can utilize Smart Search to provide the customer with the product they...

Continue reading

In-Vitro Diagnostics Market Forecast to Grow at 5.3% CAGR from 2024 to 2031 | SkyQuest Technology

Westford, June 27, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Global In-Vitro Diagnostics Market will attain a value of USD 132.90 Billion by 2031, with a CAGR of 5.3 % during the forecast period (2024-2031). The IVD sector works in a controlled setting to ensure test accuracy and patient safety. The growth of the IVD market is increasing mainly because of personalized medicine, which is an individualized approach to treatment based on a patient’s unique genetic, molecular, and clinical circumstances. Companion diagnostics, a distinct subset of IVDs, actively participates in determining whether patients are suitable for therapy or at risk of toxicity or adverse drug reactions. By eliminating unnecessary treatments, these tailored interventions not only improve the effectiveness of treatment but also keep healthcare...

Continue reading

Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights

Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development Results presented at the Annual Meeting of the AACR showed single agent MDNA11 response rate of 29% (4/14) in patients with checkpoint resistant tumors Combination dose escalation with pembrolizumab (KEYTRUDA) continues to enroll patients at the MDNA11 monotherapy expansion dose (90 µg/kg, Q2W) having cleared safety at 60 µg/kg, Q2W Approval of Clinical Trial Application by the European Medicines Agency expands the ABILITY-1 study of MDNA11 to Cancer Centers in the EU Updated MDNA11 monotherapy expansion and combination escalation results to be presented at medical...

Continue reading

Dimensional Fund Advisors Ltd. : Form 8.3 – BRITVIC PLC

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION     (a) Full name of discloser: Dimensional Fund Advisors Ltd. in its capacity as investment advisor and on behalf its affiliates who are also investment advisors (”Dimensional”). Dimensional expressly disclaims beneficial ownership of the shares described in this form 8.3.  (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Britvic...

Continue reading

Audi Selects Cerence Generative AI to Expand Capabilities of its In-Car Assistant

Audi will deploy Cerence Chat Pro to current and upcoming models, delivering added intelligence in its in-car assistant BURLINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today announced that Audi, part of the Volkswagen Group, will leverage generative AI from Cerence to expand the capabilities of its in-car assistant. With a dual focus on creating added value for cars already on the road as well as advancing its in-car assistant capabilities for the future, Audi will first deploy Cerence Chat Pro in Audi vehicles equipped with the MIB 3 infotainment platform, beginning with model year 2021 via back-end activation as well as upcoming models. In addition, Cerence Chat Pro will be integrated as part of Audi’s in-car assistant, extending its capabilities within HCP3, the new,...

Continue reading

Freshworks Report Reveals AI Is Delivering Strong Productivity Gains and Unlocking Higher-Value Work for Employees

More than half of knowledge workers are actively using AI at work—and driving efficiencies of nearly 24 business days of work per yearFreshworks 2024 Global AI Workplace ReportThe report reveals how various workplace departments are interacting with AI since the new era of generative AI exploded into the market 18 months ago.SAN MATEO, Calif., June 27, 2024 (GLOBE NEWSWIRE) — Freshworks Inc. (NASDAQ: FRSH) released its new Global AI Workplace Report today, revealing how various workplace departments are interacting with AI since the new era of generative AI exploded into the market 18 months ago. The global survey of 7,000+ full-time employees, collected from March 9 to April 4, 2024, revealed how AI has become a tool commonly used among knowledge workers – more than half (55%) of workers surveyed said they are currently...

Continue reading

Optiva Wins Prestigious “Enterprise eSIM Solution of the Year” Award

MVNOs World Congress 2024 has recognized Optiva BSS Platform for powering innovative eSIM business opportunities to drive new revenue streams across 5G, IoT and new verticals TORONTO, June 27, 2024 (GLOBE NEWSWIRE) — Optiva Inc. (TSX: OPT), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today announced its recognition as a winner of a key MVNOs World Congress Award. The prestigious platform for the MVNOs industry selected Optiva in the “Enterprise eSIM Solution of the Year” category, highlighting its role as a solution provider that has successfully partnered with MVNOs to deliver an innovative, reliable and cost-effective enterprise eSIM solution. eSIM technology is a principal component of “The Invisible Network Era,” enabling...

Continue reading

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024. The forum will include panels exploring key therapeutic themes across the fields of immunology and inflammation (I&I) and metabolism. About AquestiveAquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies. We are developing orally administered products to deliver...

Continue reading

Kandi Technologies Group Expands UTV Portfolio with Innovator e10K

JINHUA, CHINA, June 27, 2024 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (NASDAQ GS: KNDI) (“Kandi” or the “Company”), a leader in all-electric personal transportation and utility vehicles, announced the expansion of its UTV portfolio with the launch of the Innovator e10K. This new electric UTV combines strong performance with an eco-friendly design, ideal for eco-conscious adventurers seeking a powerful and precise off-road experience. The Innovator e10K features dual AC electric motors with a 10,000-watt output, an 11.52 kWh lithium battery, and a J1772 charging port. It reaches speeds up to 40 MPH with an estimated range of 60 miles and fully recharges in 8 hours using a standard 120V outlet. With compact dimensions, high ground clearance, and rugged tires, the vehicle is designed for agility and ease of handling. It...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.